{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:34Z","timestamp":1792513054978,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41591-025-04012-y","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:01:59Z","timestamp":1763632919000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Factor IX-Padua AAV gene therapy in hemophilia B: phases 1\/2 and 3 trials"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-3924","authenticated-orcid":false,"given":"Feng","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mankai","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-7695","authenticated-orcid":false,"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChangCheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengmin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-2441","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-7377","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"4012_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava, A. et al. WFH guidelines for the management of haemophilia, 3rd edition. Haemophilia 26, 1\u2013158 (2020).","journal-title":"Haemophilia"},{"key":"4012_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S2352-3026(23)00037-6","volume":"10","author":"A Srivastava","year":"2023","unstructured":"Srivastava, A. et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 10, 322\u2013332 (2023).","journal-title":"Lancet Haematol."},{"key":"4012_CR3","first-page":"884","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. FDA approves first anti-TFPI antibody for haemophilia A and B. Nat. Rev. Drug Discov. 23, 884 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4012_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hae.14484","volume":"28","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Demographics, clinical profile and treatment landscape of patients with haemophilia B in China. Haemophilia 28, 56\u201360 (2022).","journal-title":"Haemophilia"},{"key":"4012_CR5","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in haemophilia B. N. Engl. J. Med. 365, 2357\u20132365 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR6","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George, L. A. et al. Haemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215\u20132227 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S2352-3026(22)00178-8","volume":"9","author":"LA George","year":"2022","unstructured":"George, L. A. Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success. Lancet Haematol. 9, 465\u2013466 (2022).","journal-title":"Lancet Haematol."},{"key":"4012_CR8","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1016\/j.ymthe.2022.06.002","volume":"30","author":"BJ Samelson-Jones","year":"2022","unstructured":"Samelson-Jones, B. J. Worldwide use of factor IX Padua for haemophilia B gene therapy. Mol. Ther. 30, 2394\u20132396 (2022).","journal-title":"Mol. Ther."},{"key":"4012_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","volume":"387","author":"P Chowdary","year":"2022","unstructured":"Chowdary, P. et al. Phase 1\u20132 trial of AAVS3 gene therapy in patients with haemophilia B. N. Engl. J. Med. 387, 237\u2013247 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-3026(24)00006-1","volume":"11","author":"M Coppens","year":"2024","unstructured":"Coppens, M. et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. Lancet Haematol. 11, 265\u2013275 (2024).","journal-title":"Lancet Haematol."},{"key":"4012_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe, S. W. et al. Gene therapy with etranacogene dezaparvovec for haemophilia B. N. Engl. J. Med. 388, 706\u2013718 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo, Y. A. Etranacogene dezaparvovec: first approval. Drugs 83, 347\u2013352 (2023).","journal-title":"Drugs"},{"key":"4012_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. Fidanacogene elaparvovec: first approval. Drugs 84, 479\u2013486 (2024).","journal-title":"Drugs"},{"key":"4012_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S2352-3026(22)00113-2","volume":"9","author":"F Xue","year":"2022","unstructured":"Xue, F. et al. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol. 9, 504\u2013513 (2022).","journal-title":"Lancet Haematol."},{"key":"4012_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1056\/NEJMc2211173","volume":"387","author":"F Xue","year":"2022","unstructured":"Xue, F. et al. Total knee arthroplasty after gene therapy for haemophilia B. N. Engl. J. Med. 387, 1622\u20131624 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","volume":"391","author":"A Cuker","year":"2024","unstructured":"Cuker, A. et al. Gene therapy with fidanacogene elaparvovec in adults with haemophilia B. N. Engl. J. Med. 391, 1108\u20131118 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR17","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","volume":"392","author":"JEJ Rasko","year":"2025","unstructured":"Rasko, J. E. J. et al. Fidanacogene elaparvovec for haemophilia B\u2014a multiyear follow-up study. N. Engl. J. Med. 392, 1508\u20131517 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR18","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","volume":"8","author":"SR Deshpande","year":"2024","unstructured":"Deshpande, S. R. et al. Adeno-associated virus\u2013based gene therapy for haemophilia A and B: a systematic review and meta-analysis. Blood Adv. 8, 5957\u20135974 (2024).","journal-title":"Blood Adv."},{"key":"4012_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno, C. S. et al. Successful transduction of liver in haemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342\u2013347 (2006).","journal-title":"Nat. Med."},{"key":"4012_CR20","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/mt.2011.81","volume":"19","author":"H Li","year":"2011","unstructured":"Li, H. et al. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol. Ther. 19, 2021\u20132030 (2011).","journal-title":"Mol. Ther."},{"key":"4012_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23\u201336 (2013).","journal-title":"Blood"},{"key":"4012_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/v11020102","volume":"11","author":"J Rabinowitz","year":"2019","unstructured":"Rabinowitz, J., Chan, Y. K. & Samulski, R. J. Adeno-associated virus (AAV) versus immune response. Viruses 11, 102 (2019).","journal-title":"Viruses"},{"key":"4012_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera, H. C., Kuranda, K. & Mingozzi, F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol. Ther. 28, 723\u2013746 (2020).","journal-title":"Mol. Ther."},{"key":"4012_CR24","volume":"130","author":"S Pipe","year":"2017","unstructured":"Pipe, S. et al. 101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe haemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX). Blood 130, 3331 (2017).","journal-title":"Blood"},{"key":"4012_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.2019004625","volume":"137","author":"BA Konkle","year":"2021","unstructured":"Konkle, B. A. et al. BAX 335 haemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood 137, 763\u2013774 (2021).","journal-title":"Blood"},{"key":"4012_CR26","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.jtha.2024.12.038","volume":"23","author":"MC Ozelo","year":"2025","unstructured":"Ozelo, M. C. et al. Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study. J. Thrombosis Haemost. 23, 1496\u20131506 (2025).","journal-title":"J. Thrombosis Haemost."},{"key":"4012_CR27","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","volume":"22","author":"B Madan","year":"2024","unstructured":"Madan, B. et al. Three-year outcomes of valoctocogene roxaparvovec gene therapy for haemophilia A. J. Thrombosis Haemost. 22, 1880\u20131893 (2024).","journal-title":"J. Thrombosis Haemost."},{"key":"4012_CR28","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","volume":"7","author":"A Von Drygalski","year":"2022","unstructured":"Von Drygalski, A. et al. Stable and durable factor IX levels in haemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv. 7, 5671\u20135679 (2022).","journal-title":"Blood Adv."},{"key":"4012_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi, K. J. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for haemophilia A. N. Engl. J. Med. 382, 29\u201340 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR30","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George, L. A. et al. Multiyear factor VIII expression after AAV gene transfer for haemophilia A. N. Engl. J. Med. 385, 1961\u20131973 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4012_CR31","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/jth.15281","volume":"19","author":"MM Robinson","year":"2021","unstructured":"Robinson, M. M. et al. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J. Thrombosis Haemost. 19, 1212\u20131218 (2021).","journal-title":"J. Thrombosis Haemost."},{"key":"4012_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hae.14484","volume":"28","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Demographics, clinical profile and treatment landscape of participants with haemophilia B in China. Haemophilia 28, 56\u201360 (2022).","journal-title":"Haemophilia"},{"key":"4012_CR33","doi-asserted-by":"publisher","first-page":"e26077","DOI":"10.1097\/MD.0000000000026077","volume":"100","author":"R Yang","year":"2021","unstructured":"Yang, R. et al. First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric haemophilia B population in China. Medicine 100, e26077 (2021).","journal-title":"Medicine"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04012-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04012-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:02:52Z","timestamp":1769007772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04012-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4012"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04012-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6138866\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.Z., X.W., Z.D., W.J., C.Y. and X.X. are employees of Belief Biomed. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}